English Ukrainian
Clinical medicine

NITRIC OXIDE – A BIOMARKER OF THE PROGRESS AND METASTASIS OF RENAL CELL CANCER INTO THE BRAIN

Published 2024-08-28

Authors:

V.N. Komarevtsev
K.V. Balabanova
I.V. Kalinin
S.A. Usatov
M.O. Ovcharenko
I.O. Komarevtseva
I.I. Zielonyi
Abstract:
Endogenous nitric oxide plays a pivotal role in cancer development. The purpose of the study was to investigate the role of the biomarker of nitric oxide metabolites in the progression and metastasis of renal cell carcinoma to the brain. To test our hypothesis, this case-control study consisted of the indicators of nitric oxide metabolites in the inactive parenchyma resected during operations for urolithiasis (the comparison group, n=13); 103 patients with renal cell carcinoma. To analyze the metabolites of nitric oxide, we used a technique that allows us to determine the content of nitrite and nitrate ions in the same sample. The content of stable metabolites of nitric oxide was expressed in μg/mg protein in tissues. Levels of nitric oxide metabolites were significantly higher (1.5-fold higher) in tumor tissue than in peri-tumor tissue. Nitric oxide exhibits a pro- or antitumorigenic effect depending on the level of NO and the stage of the tumor process. The level of nitric oxide in tumor tissue was an independent predictor of renal cell carcinoma progression and its metastasis to the brain. The content of nitric oxide in peri-tumor tissue has a high prognostic efficacy in renal cell carcinoma metastasis and as a protective factor that prevents tumor progression.
Keywords:
renal cell carcinoma brain metastasis nitric oxide
References:
  1. Komarevtseva ІО, Orlova OA, Blagodarenko YA. Bіfunktsіonalnyi kharakter dіi oksydu azotu v nyrkovykh tkanynakh pry aktyvatsіi apoptozu. Ukraiinskyi Bіokhіmіchnyi zhurnal. 2002. 74(4a) (dodatok 1):47. [in Ukrainian].
  2. Dagher J, Delahunt B, Rioux-Leclercq N, Egevad L, Srigley JR, Coughlin G, et al. Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading. Histopathology. 2017 Dec;71(6):918–925. doi: 10.1111/his.13311.
  3. Ene CD, Tampa M, Georgescu SR. Disturbances in Nitric Oxide Cycle and Related Molecular Pathways in Clear Cell Renal Cell Carcinoma. Cancers (Basel). 2023;15(24). doi:10.3390/cancers15245797.
  4. Gào X, Schöttker B. Reduction–oxidation pathways involved in cancer development: a systematic review of literature reviews. Oncotarget. 2017; 8(31):51888–51906. doi: 10.18632/oncotarget.17128.
  5. Ghasemi A. Quantitative aspects of nitric oxide production from nitrate and nitrite. Excli J. 2022;21:470–486. doi: 10.17179/excli2022-4727.
  6. Hu Y, Xiang J, Su L, Tang X. The regulation of nitric oxide in tumor progression and therapy. J. Int. Med. Res. 2020;48:0300060520905985. doi: 10.1177/0300060520905985.
  7. Mazurek M, Rola R. The implications of nitric oxide metabolism in the treatment of glial tumors. Neurochem Int. 2021;150. doi:10.1016/j.neuint.2021.105172.
  8. Moran H, Cancel LM, Huang P, Roberge S, Xu T, Tarbell JM, et al. Glycocalyx mechanotransduction mechanisms are involved in renal cancer metastasis. Matrix Biol Plus. 2022;13. doi:10.1016/j.mbplus.2021.100100.
  9. Salihi A, Al-Naqshabandi MA, Khudhur ZO, Housein Z, Hama HA, Abdullah RM, et al. Gasotransmitters in the tumor microenvironment: Impacts on cancer chemotherapy. Mol Med Rep. 2022;26(1). doi:10.3892/mmr.2022.12749.
  10. Sashegyi A, Ferry D. On the Interpretation of the Hazard Ratio and Communication of Survival Benefit. Oncologist. 2017;22(4):484–486. doi:10.1634/theoncologist.2016-0198.
  11. Sciacovelli M, Dugourd A, Jimenez LV, Yang M, Nikitopoulou E, Costa ASH, et al. Nitrogen partitioning between branched-chain amino acids and urea cycle enzymes sustains renal cancer progression. bioRxiv. 2021 doi: 10.1101/2021.09.17.460635.
  12. Somasundaram V, Basudhar D, Bharadwaj G, No JH, Ridnour LA, Cheng RYS, et al. Molecular mechanisms of nitric oxide in cancer progression, signal transduction, and metabolism. Antioxidants Redox Signal. 2019;30:1124–1143. doi: 10.1089/ars.2018.7527.
  13. Takemura K, Lemelin A, Ernst MS, Wells JC, Saliby RM, El Zarif T, et al. Outcomes of Patients with Brain Metastases from Renal Cell Carcinoma Receiving First-line Therapies: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2024 S0302–2838(24)00005-8. doi: 10.1016/j.eururo.2024.01.006.
Publication:
«World of Medicine and Biology» Vol. 20 No. 89 (2024) , с. 82-88
УДК 616.61-006:616.65+576.367
DOI:
https://doi.org/10.26724/2079-8334-2024-3-89-82-88